anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Studies have shown that eosinophilic COPD (eCOPD) is a distinct phenotype of the disease. It is well established that innate lymphoid cells are involved in the development of eosinophilic inflammation. Interleukin(IL)-25, thymic stromal lymphopoietin (TSLP) and IL-33 are a group of cytokines produced by epithelium in response to danger signals, e.g., cigarette smoke, and potent activators of ILC2s. In the present study, we examined circulating and sputum ILC2 numbers and expression of intracellular IL-5 as well as receptors for TSLP, IL-33 and IL-25 by ILC2s in non-atopic COPD patients with and without (neCOPD) airway eosinophilic inflammation and healthy smokers. In addition, we examined the association between ILC2s and clinical indicators of COPD burden (i.e., symptom intensity and risk of exacerbations). ILC2s were enumerated in peripheral blood and induced sputum by means of flow cytometry. We noted significantly greater numbers of airway IL-5+ILC2s and TSLPR+ILC2s in eCOPD compared with neCOPD (p < 0.05 and p < 0.01, respectively) and HSs (p < 0.001 for both). In addition, we showed that IL-5+ILC2s, IL-17RB+ILC2s and ST2+ILC2s are significantly increased in the sputum of eCOPD patients compared with HSs. In all COPD patients, sputum ILC2s positively correlated with sputum eosinophil percentage (r = 0.48, p = 0.002). We did not find any significant correlations between sputum ILC2s and dyspnea intensity as measured by the modified Medical Research Council scale (mMRC) and symptom intensity measured by the COPD Assessment Test (CAT). These results suggest the involvement of epithelial alarmin-activated ILC2s in the pathobiology of eosinophilic COPD.
Gut microbiota contributes to the homeostasis of immune system and is related to various diseases such as tumorigenesis. Ferroptosis, a new type of cell death, is also involved in the disease pathogenesis. Recent studies have found the correlations of gut microbiota mediated ferroptosis and immune cell death. Gut microbiota derived immunosuppressive metabolites, which can promote differentiation and function of immune cells, tend to inhibit ferroptosis through their receptors, whereas inflammatory metabolites from gut microbiota also affect the differentiation and function of immune cells and their ferroptosis. Thus, it is possible for gut microbiota to regulate immune cell ferroptosis. Indeed, gut microbiota metabolite receptor aryl hydrocarbon receptor (AhR) can affect ferroptosis of intestinal intraepithelial lymphocytes, leading to disease pathogenesis. Since immune cell ferroptosis in tumor microenvironment (TME) affects the occurrence and development of tumor, the modulation of gut microbiota in these cell ferroptosis might influence on the tumorigenesis, and also immunotherapy against tumors. Here we will summarize the recent advance of ferroptosis mediated by gut microbiota metabolites, which potentially acts as regulator(s) on immune cells in TME for therapy against tumor.
The present invention relates to treatment of diseases and disorders of the immune system comprising treatment of deficiencies within the immune defence system. The invention concerns preparation of a novel expression construct encoding human MBL, a novel recombinant preparation of human MBL with high similarity to natural human MBL and futhermore it comprises use of this compound in compositions, medicaments and in methods for treatment of conditions such as those related to immunosuppressive conditions and/or to conditions of MBL deficiencies including latent conditions. Conditions of deficiencies of Mannan-Binding Lectin (MBL) are associated with increased susceptibility to infections. In more particular, the invention concerns treatment of said conditions, including latent conditions, i.e. although there is no present need. The treatment is aimed at humans and at animals, in which the immune system appears to act similarly to the human immune system.
The single-group intervention will be the adapted-CCI 4D-cycle caries care, with non-AGP and reduced in-office appointments' time. A trained examiner per centre will conduct examinations at baseline, at 5-5.5 months (three months after basic management), 8.5 and 12 months, assessing the child's CCI caries risk and oral-health behaviour, visually staging and assessing caries-lesions severity and activity without air-drying (ICDAS-merged Epi); fillings/sealants; missing/dental-sepsis teeth, and tooth symptoms, synthetizing together with parent and external-trained dental practitioner (DP) the patient- and tooth-surface level diagnoses and personalised care plan. DP will deliver the adapted-CCI caries care. Parents' and dentists' process acceptability will be assessed via Treatment-Evaluation-Inventory questionnaires, and costs in terms of number of appointments and activities. Twenty-one centres in 13 countries will participate.
Coronary artery disease (CAD) is the leading cause of death in industrialized countries. Current revascularization therapies are PCI or surgical revascularization. However, inherent to them are procedure-related risks and the fact, that progression of CAD is not prevented. Additionally, up to one fourth of all CAD patients are not amenable to standard revascularization therapies. Thus, there is a need for alternative therapies. The coronary collateral circulation is prevalent in humans, and in CAD the amount of collateral flow is a pivotal protective factor with respect to infarct size, all-cause- and cardiac mortality. Coronary collateral growth promotion is an alternative to conventional revascularization which can be achieved by cytokine-based approaches (e.g. with colony-stimulating factor-therapy) in humans. The goal of collateral promotion is to reduce myocardial damage in case of a coronary occlusion.
Individuals with intellectual and developmental disabilities face barriers to accessing sex education, including a lack of professional ownership over providing sex education. Limited information exists regarding educator training background, funding structure, and who they serve. We interviewed 58 sex educators of individuals with intellectual and developmental disabilities. We integrated thematic analysis and composite narratives to identify service models and the benefits and challenges associated with them. We identified seven service delivery models: clinic-based board-certified behavior analysis; mental health therapists; small businesses; public health not-for-profits; disability programs; high school-based educators; and university-based educators; and three themes that addressed the strengths and challenges of these service models: Instructional Implications of the Short-term, Drop-in Approach; Getting on the Same Page; and Questioning Who Should Teach Sex Education. Understanding these typologies and their strengths and challenges provide insights into how we can build capacity for sex education services.
First, participants will be taught to implement a 20-second self-compassion induction via video recording. Second, participants will be taught to choose a cue that will precede their daily use of the self-compassion induction. Participants will document the cue they chose, and will be emailed a record of their selected cue, along with the recording and transcript of the self-compassion induction that they can refer back to for reference. Third, participants will be asked to use the self-compassion induction as much as they can and at least once during their daily routine following exposure to their chosen cue.
A medical image display apparatus includes a storage unit, a display unit, and an input unit. The storage unit is configured to store examination information of a plurality of examinations and image data resulting from the plurality of examinations. The display unit is configured to display a plurality of selectable icons corresponding to the plurality of examinations along one of a vertical direction and a horizontal direction in a screen. The display unit is also configured to display one or more selectable thumbnail images along the other one of the vertical direction and the horizontal direction. The display unit is still further configured to display an original image based on the image data. Each of the one or more selectable thumbnail images is displayed in a smaller size than the original image. The input unit is configured to select a first of the plurality of selectable icons and a first of the one or more selectable thumbnail images. The one or more selectable thumbnail images belong to a first of the plurality of examinations which corresponds to the first selectable icon. The original image corresponds to the first selectable thumbnail image.
Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: pain, temperature, touch, proprioception, and skeletal muscle tone.

Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block and ultimately to cardiac arrest. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.

Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression, or both. Apparent central stimulation is manifested as restlessness, tremors, and shivering, progressing to convulsions, followed by depression and coma progressing ultimately to respiratory arrest. However, the local anesthetics have a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited stage.

A clinical study using 15 mL of 2% epidural mepivacaine at the T 9-10 interspace in 62 patients, 20 to 79 years of age, demonstrated a 40% decrease in the amount of mepivacaine required to block a given number of dermatomes in the elderly (60 to 79 years, N=13) as compared to young adults 20 to 39 years. 

Another study using 10 mL of 2% lumbar epidural mepivacaine in 161 patients, 19 to 75 years of age, demonstrated a strong inverse relationship between patient age and the number of dermatomes blocked per cc of mepivacaine injected.
Background This research is designed through randomization, control, and double-blind trial to explore the clinical effectiveness of intravenous laser irradiation of blood for knee degenerative arthritis; and to explore the changes in body's balance function. Furthermore to establish a new way of clinical rehabilitation therapy. The research will further study the special expression of blood cells after the treatment and as well as the molecular mechanism of low-energy intravenous laser therapy on hematopoietic stem cells. fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes. Pain control is indicated in such treatment, but still lacking evidence of improving the symptoms of degenerative knee arthritis.

Purpose This research is designed through randomization, control, and double-blind trial to explore the clinical effectiveness of intravenous laser irradiation of blood for knee degenerative arthritis; and to explore the changes in body's balance function. Furthermore to establish a new way of clinical rehabilitation therapy. The research will further study the special biomarker to investigate the mechanism of low-energy intravenous laser therapy for osteoarthritis.

Method The investigators plan to recruit 20 patients who are between the ages of 50 to 75 years old, but younger than 75 years old. The participants are required to have clear conscious and be able to communicate. Their symptoms of degenerative arthritis could be one or both knees which last more than six months; with knee pain greater than 4 points when walking. The treatment group will receive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 \~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity. This plan will be explained to the patient in detail during the outpatient visit and patients will sign the consent form upon agreement. Before intravenous laser irradiation, three days, one month, and three months after the therapy, 20 ml of autologous peripheral venous blood need to be drawn for basic blood tests and biomarker tests. At the same time, the clinical functions of patients will be evaluated, including visual analogous scale, Lequesne 's severity index, WOMAC scale, and balance function test.
FIELD: veterinary microbiology, biotechnology. SUBSTANCE: industrial strains of Salmonella choleraesuis and Salmonella typhimurium are cultured in nutrient medium containing Hottinger broth at pH 7.6-7.8 and index of amine nitrogen 200-250 mg%. Obtained bacterial mixture is subjected for inactivation with aminoethylethyleneimine which is added to bacterial suspension up to concentration 0.5-4%. Mixture is incubated at 37-38 C for 12-16 h. After termination of inactivation obtained antigen is added to sucrose-gelatin medium and antigen is combined with oily adjuvant in the ratio = (2: 3)-(1: 4), respectively. EFFECT: enhanced immunogenic activity and specific safety of vaccine. 5 cl, 3 tbl, 6 ex
Zileuton is an orally active inhibitor of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Zileuton has the chemical name (±)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea and the following chemical structure:

  
  
Zileuton has the molecular formula C11H12N2O2S and a molecular weight of 236.29. It is a racemic mixture (50:50) of R(+) and S(-) enantiomers. Zileuton is a practically odorless, white, crystalline powder that is soluble in methanol and ethanol, slightly soluble in acetonitrile, and practically insoluble in water and hexane. The melting point ranges from 144.2°C to 145.2°C.

Zileuton Extended-Release Tablets for oral administration are bi-layer tablets comprising of an immediate-release layer and extended-release layer. Zileuton Extended-Release Tablets are oval shaped, biconvex tablets debossed with “656” on one side and “P” on the other side. Each tablet contains 600 mg of zileuton and the following inactive ingredients: colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, partially pregelatinized maize starch, polyethylene glycol 400, sodium lauryl sulfate, sodium starch glycolate, titanium dioxide, yellow iron oxide.
No exposure-response relationships for KALBITOR to components of the complement or kallikrein-kinin pathways have been established.

The effect of KALBITOR on activated partial thromboplastin time (aPTT) was measured because of potential effect on the intrinsic coagulation pathway. Prolongation of aPTT has been observed following intravenous dosing of KALBITOR at doses ≥20 mg/m2. At 80 mg administered intravenously in healthy subjects, aPTT values were prolonged approximately two-fold over baseline values and returned to normal by 4 hours post-dose.

For patients taking KALBITOR, no significant QT prolongation has been seen. In a randomized, placebo-controlled trial (EDEMA4) studying the 30 mg subcutaneous dose versus placebo, 12-lead ECGs were obtained at baseline, 2 hours and 4 hours post-dose (covering the time of expected Cmax), and at follow-up (day 7). ECGs were evaluated for PR interval, QRS complex, and QTc interval. KALBITOR had no significant effect on the QTc interval, heart rate, or any other components of the ECG.
The invention comprises 1, 3-dioxanes and 1, 3-dioxolanes, and their acid addition and quaternary ammonium salts, in which the carbon atom in the 2-position carries at least one carbocyclic or heterocyclic substituent (attached directly or through an alkylene or oxa-alkylene bridge and optionally substituted by one or more halogen atoms or C1-6 alkyl or alkoxy groups) or forms part of a spiro-carbocyclic ring (optionally substituted by one or more halogen atoms or C1-6 alkyl or alkoxy groups) and in which another ring carbon atom carries a piperidyl radical attached directly by one of its ring carbon atoms and optionally substituted on one or more ring carbon atoms by a halogen atom or a C1-6 alkyl or alkoxy group or on the nitrogen atom, e.g. by an alkyl, aralkyl, acyl (e.g. acetyl or diethylaminoacetyl), hydroxyalkyl or dialkylaminoalkyl group, and the preparation thereof by reacting a piperidyl-1, 2-ethanediol or -1, 3-propanediol with an aldehyde, ketone, acetal or ketal having at least one carbocyclic or heterocyclic radical attached (directly or indirectly) to the carbonyl or acetal carbon atom or with a carbocyclic ketone.  When the 2-carbon atom carries only one carbocyclic or heterocyclic substituent, the remaining valency may be satisfied by a hydrogen atom or by an alkyl, alkoxyalkyl or haloalkyl group.  The products are obtained in the form of one or more racemic mixtures, which may be resolved into their optically active antipodes.  Reference is also made to the preparation of some of the compounds by reaction of the appropriate aldehydes or ketones with piperidylethylene oxides, to the introduction of the substituents on the nitrogen atom of the piperidyl radical by alkylation or acylation, and to quaternation with alkyl halides or benzyl chloride.  Piperidylglycols used as starting mateials are prepared by catalytic hydrogenation of the corresponding pyridylglycols.  Pharmaceutical compositions.-The compounds of the invention may be formulated with conventional carriers, e.g. into gels or aqueous solutions, for use in the treatment of gastrointestinal disturbances or as antispasmodic agents.  Some of them may also be used as local anaesthetics, by infiltration or topical application.
The present invention relates to isolated recombinant proteins, in particular Themis proteins and also to methods of providing isolated recombinant themis protein. Themis (thymocyte-expressed molecule involved in selection),is a member of a family of proteins whose functions are not all known. It is highly conserved among vertebrates. Themis has been found to have high expression in thymocytes between the pre-T cell antigen receptor (pre-TCR) and positive-selection checkpoints and low expression in mature T cells. Themis protein is not easy to produce and purify in large quantities. The present invention provides an isolated, soluble protein comprising an amino acid sequence selected from: a) the sequence set out in SEQ ID NO: 1; b) the sequence of amino acids 1 to 261 of SEQ ID NO: 1; c) a sequence having at least 70% identity to a) or b); d) an active fragment or variant of a), b) or c); e) a fusion protein comprising the sequence of a), b), c) or d) and a fusion partner; f) a sequence comprising the sequence of a), b), c), d) or e) and a purification tag.
Disclosed is a novel peptide capable of biding to EpCAM, which can be produced readily by a chemical synthesis method or a genetic engineering method.  A phage population which can present various peptide sequences on phage particles is contacted with EpCAM protein immobilized on a solid support.  Phage particles which bind to EpCAM protein are collected.  The collected phage particles are proliferated in  Escherichia coli .  Subsequently, a panning procedure comprising contacting the proliferated phage particles with EpCAM protein again is repeated.  In this manner, a phage clone capable of binding specifically to EpCAM is successfully produced.  The DNA sequence of the phage clone is analyzed to specify an amino acid sequence capable of binding specifically to EpCAM.
In males but not in females, brain derived neurotrophic factor (BDNF) plays an obligatory role in the onset and maintenance of neuropathic pain. Afferent terminals of injured peripheral nerves release colony stimulating factor (CSF-1) and other mediators into the dorsal horn. These transform the phenotype of dorsal horn microglia such that they express P2X4 purinoceptors. Activation of these receptors by neuron-derived ATP promotes BDNF release. This microglial-derived BDNF increases synaptic activation of excitatory dorsal horn neurons and decreases that of inhibitory neurons. It also alters the neuronal chloride gradient such the normal inhibitory effect of GABA is converted to excitation. By as yet undefined processes, this attenuated inhibition increases NMDA receptor function. BDNF also promotes the release of pro-inflammatory cytokines from astrocytes. All of these actions culminate in the increase dorsal horn excitability that underlies many forms of neuropathic pain. Peripheral nerve injury also alters excitability of structures in the thalamus, cortex and mesolimbic system that are responsible for pain perception and for the generation of co-morbidities such as anxiety and depression. The weight of evidence from male rodents suggests that this preferential modulation of excitably of supra-spinal pain processing structures also involves the action of microglial-derived BDNF. Possible mechanisms promoting the preferential release of BDNF in pain signaling structures are discussed. In females, invading T-lymphocytes increase dorsal horn excitability but it remains to be determined whether similar processes operate in supra-spinal structures. Despite its ubiquitous role in pain aetiology neither BDNF nor TrkB receptors represent potential therapeutic targets.
We intend to study a new, non-invasive fetal intervention to help outcomes in children with LHH. We plan to study the effect of giving oxygen to mothers who have fetuses with small left-sided structures. We specifically will evaluate if the fetal left heart valves will grow faster if the mother breathes extra oxygen on a daily basis (at least 8 hours per day). Mothers and fetuses meeting criteria will be offered to enroll in the study. All enrolled mothers will be asked to receive oxygen continuously for the rest of the pregnancy using a non-rebreather mask. At birth, we will compare the fetuses whose mothers received oxygen to historical controls. We specifically will study how fast the left heart valves have grown.